{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T06:11:54Z","timestamp":1793686314669,"version":"4.5.1"},"reference-count":206,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Rheumatic and musculoskeletal diseases (RMDs) confer an increased cardiovascular risk beyond traditional factors, with peripheral artery disease (PAD) being an important source of morbidity and disability in these patients. This review summarizes current evidence on PAD across RMDs, including rheumatoid arthritis, systemic lupus erythematosus, antiphospholipid syndrome, systemic sclerosis, polymyalgia rheumatica, psoriatic arthritis, and primary Sj\u00f6gren\u2019s syndrome. Physiopathological mechanisms involved include persistent inflammation, immune dysregulation, and the presence of pathogenic autoantibodies. Protective humoral responses have also been linked to reduced CV risk and may serve as future biomarkers. Clinical studies reveal variable PAD prevalence across diseases but consistent high underdiagnosis. Optimal management requires aggressive CV risk control, including lipid-lowering, immunomodulatory, and biologic therapies. This review underscores PAD as a distinct and clinically relevant manifestation of systemic autoimmunity, calling for targeted screening and prevention strategies in rheumatic populations.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1814953","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T05:50:14Z","timestamp":1776837014000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Atherosclerosis features in rheumatic diseases \u2013 focus on peripheral artery disease"],"prefix":"10.3389","volume":"17","author":[{"given":"Alexandr","family":"Ceasovschih","sequence":"first","affiliation":[{"name":"Grigore T. Popa University of Medicine and Pharmacy","place":["Iasi, Romania"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina","family":"Dima","sequence":"additional","affiliation":[{"name":"Clinical Department 5, Faculty of Medicine, Carol Davila University of Medicine and Pharmacy","place":["Bucharest, Romania"]},{"name":"Department of Rheumatology, Colentina Clinical Hospital","place":["Bucharest, Romania"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Rodriguez-Carrio","sequence":"additional","affiliation":[{"name":"Area of Immunology, Department of Functional Biology, Faculty of Medicine, University of Oviedo","place":["Oviedo, Spain"]},{"name":"Basic and Translational Research on Inflammatory Diseases, Department of Metabolism, Instituto de Investigaci\u00f3n Sanitaria del Principado de Asturias (ISPA)","place":["Oviedo, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia","family":"Balta","sequence":"additional","affiliation":[{"name":"Grigore T. Popa University of Medicine and Pharmacy","place":["Iasi, Romania"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raluca-Elena","family":"Alexa","sequence":"additional","affiliation":[{"name":"Grigore T. Popa University of Medicine and Pharmacy","place":["Iasi, Romania"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca Codrina","family":"Morarasu","sequence":"additional","affiliation":[{"name":"Grigore T. Popa University of Medicine and Pharmacy","place":["Iasi, Romania"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catalina","family":"Lionte","sequence":"additional","affiliation":[{"name":"Grigore T. Popa University of Medicine and Pharmacy","place":["Iasi, Romania"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fotios","family":"Barkas","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Faculty of Medicine, School of Health Sciences, University of Ioannina","place":["Ioannina, Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maciej","family":"Banach","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, John Paul II Catholic University of Lublin","place":["Lublin, Poland"]},{"name":"Department of Preventive Cardiology and Lipidology, Medical University of Lodz (MUL)","place":["Lodz, Poland"]},{"name":"Ciccarone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine","place":["Baltimore MD, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victorita","family":"Sorodoc","sequence":"additional","affiliation":[{"name":"Grigore T. Popa University of Medicine and Pharmacy","place":["Iasi, Romania"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurentiu","family":"Sorodoc","sequence":"additional","affiliation":[{"name":"Grigore T. Popa University of Medicine and Pharmacy","place":["Iasi, Romania"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2024.176338","article-title":"Hegemony of inflammation in atherosclerosis and coronary artery disease","volume":"966","author":"Attiq","year":"2024","journal-title":"Eur J Pharmacol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1038\/s41419-024-07166-8","article-title":"Inflammation in atherosclerosis: pathophysiology and mechanisms","volume":"15","author":"Ajoolabady","year":"2024","journal-title":"Cell Death Dis"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2025.08.015","article-title":"Global, regional, and national burden of cardiovascular diseases and risk factors in 204 countries and territories, 1990-2023","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2023.101999","article-title":"Accelerated atherosclerosis and management of cardiovascular risk in autoimmune rheumatic diseases: an updated review","volume":"48","author":"Karakasis","year":"2023","journal-title":"Curr Probl Cardiol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221733","article-title":"EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome","volume":"81","author":"Drosos","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.121.319822","article-title":"Inflammation resolution: implications for atherosclerosis","volume":"130","author":"Doran","year":"2022","journal-title":"Circ Res"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.mvr.2024.104713","article-title":"Oxidative stress and vascular dysfunction: potential therapeutic targets and therapies in peripheral artery disease","volume":"155","author":"Allen","year":"2024","journal-title":"Microvasc Res"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3390\/jvd4020021","article-title":"Peripheral artery disease: atherosclerosis, decreased nitric oxide, and vascular arterial stiffening","volume":"4","author":"Hayden","year":"2025","journal-title":"JVD"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3390\/jcdd11070206","article-title":"Systematic review on the role of IL-6 and IL-1\u03b2 in cardiovascular diseases","volume":"11","author":"Katkenov","year":"2024","journal-title":"J Cardiovasc Dev Dis"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1507420","article-title":"The role of splicing events in the inflammatory response of atherosclerosis: molecular mechanisms and modulation","volume":"15","author":"Wang","year":"2024","journal-title":"Front Immunol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/s41392-022-00955-7","article-title":"Inflammation and atherosclerosis: signaling pathways and therapeutic intervention","volume":"7","author":"Kong","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"B12","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s10875-006-9022-6","article-title":"Matrix metalloproteinase-9 and autoimmune diseases","volume":"26","author":"Ram","year":"2006","journal-title":"J ClinImmunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1285455","article-title":"Immunomodulatory roles of metalloproteinases in rheumatoid arthritis","volume":"14","author":"Bian","year":"2023","journal-title":"Front Pharmacol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaf658","article-title":"C-reactive protein and cardiovascular risk among women with no standard modifiable risk factors: evaluating the \u2018SMuRF-less but inflamed.\u2019","author":"Ridker","year":"2025","journal-title":"Eur Heart J"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2018.02.005","article-title":"Interleukin-6 is an independent predictor of progressive atherosclerosis in the carotid artery: the Troms\u00f8 study","volume":"271","author":"Eltoft","year":"2018","journal-title":"Atherosclerosis"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.122.320877","article-title":"Interleukin-6 predicts carotid plaque severity, vulnerability, and progression","volume":"131","author":"Kamtchum-Tatuene","year":"2022","journal-title":"Circ Res"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s11883-024-01259-7","article-title":"IL-6 and cardiovascular risk: a narrative review","volume":"27","author":"Mehta","year":"2024","journal-title":"Curr Atheroscler Rep"},{"key":"B18","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.jvssci.2022.05.039","article-title":"Interleukin-6 levels and cardiovascular events in the cardiovascular inflammation reduction trial: consistent associations for incident coronary, cerebrovascular, and peripheral artery disease","volume":"3","author":"Marinho","year":"2022","journal-title":"JVS-Vascular Sci"},{"key":"B19","volume-title":"C-reactive protein: clinical relevance and interpretation","author":"Singh","year":"2025"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.mpmed.2025.08.004","article-title":"The burden of rheumatic and musculoskeletal disease","volume":"53","author":"Verstappen","year":"2025","journal-title":"Medicine"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10194427","article-title":"Autoimmune rheumatic diseases and vascular function: the concept of autoimmune atherosclerosis","volume":"10","author":"Hedar","year":"2021","journal-title":"J Clin Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-020-04616-2","article-title":"The lipid paradox in rheumatoid arthritis: the dark horse of the augmented cardiovascular risk","volume":"40","author":"Venetsanopoulou","year":"2020","journal-title":"Rheumatol Int"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21249505","article-title":"The lipid paradox as a metabolic checkpoint and its therapeutic significance in ameliorating the associated cardiovascular risks in rheumatoid arthritis patients","volume":"21","author":"Behl","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.135871","article-title":"Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease","volume":"70","author":"Myasoedova","year":"2011","journal-title":"Ann Rheumatic Dis"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.104.507996","article-title":"Accelerated atherosclerosis in autoimmune rheumatic diseases","volume":"112","author":"Shoenfeld","year":"2005","journal-title":"Circulation"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22115770","article-title":"Antibody-based therapeutics for atherosclerosis and cardiovascular diseases","volume":"22","author":"Ji","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3258","article-title":"Local proliferation dominates lesional macrophage accumulation in atherosclerosis","volume":"19","author":"Robbins","year":"2013","journal-title":"Nat Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3390\/cells10040951","article-title":"Targeting inflammatory pathways in cardiovascular disease: the inflammasome, interleukin-1, interleukin-6 and beyond","volume":"10","author":"Libby","year":"2021","journal-title":"Cells"},{"key":"B29","article-title":"Autoantibodies to ox-LDL in Sj\u00f6gren\u2019s syndrome: are they atheroprotective","author":"Cinoku","year":"2018","journal-title":"Clin Exp Rheumatol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3390\/antiox13121560","article-title":"Overview of clinical relevance of antibodies against oxidized low-density lipoprotein (oLAb) within three decades by ELISA technology","volume":"13","author":"Wonisch","year":"2024","journal-title":"Antioxidants (Basel)"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.2174\/1570161118666200514222236","article-title":"Cardio-rheumatology: cardiovascular complications in systemic autoimmune rheumatic diseases \/ is inflammation the common link and target","volume":"18","author":"Manolis","year":"2020","journal-title":"CVP"},{"key":"B32","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.atherosclerosis.2008.11.020","article-title":"Identification of the target for therapeutic recombinant anti-apoB-100 peptide antibodies in human atherosclerotic lesions","volume":"205","author":"Gon\u00e7alves","year":"2009","journal-title":"Atherosclerosis"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.115.306938","article-title":"Low levels of apolipoprotein B-100 autoantibodies are associated with increased risk of coronary events","volume":"36","author":"Bj\u00f6rkbacka","year":"2016","journal-title":"ATVB"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.112622","article-title":"HDL regulates the risk of cardiometabolic and inflammatory-related diseases: focusing on cholesterol efflux capacity","volume":"138","author":"Kang","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.plipres.2012.03.003","article-title":"Dysfunctional HDL: a novel important diagnostic and therapeutic target in cardiovascular disease","volume":"51","author":"Otocka-Kmiecik","year":"2012","journal-title":"Prog Lipid Res"},{"key":"B36","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.atherosclerosis.2017.10.018","article-title":"HDL functionality in type 1 diabetes","volume":"267","author":"Ganjali","year":"2017","journal-title":"Atherosclerosis"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1002\/art.27286","article-title":"Antibodies to apolipoprotein A-I, high-density lipoprotein, and C-reactive protein are associated with disease activity in patients with systemic lupus erythematosus","volume":"62","author":"O\u2019Neill","year":"2010","journal-title":"Arthritis Rheum"},{"key":"B38","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s00403-019-01986-x","article-title":"Antibodies towards high-density lipoprotein components in patients with psoriasis","volume":"312","author":"Paiva-Lopes","year":"2020","journal-title":"Arch Dermatol Res"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kead009","article-title":"Humoral responses against HDL are linked to lipoprotein traits, atherosclerosis, inflammation and pathogenic pathways during early arthritis stages","volume":"62","author":"Rodr\u00edguez-Carrio","year":"2023","journal-title":"Rheumatol (Oxford)"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2019.00211","article-title":"IgG anti-high-density lipoproteins antibodies discriminate between arterial and venous events in thrombotic antiphospholipid syndrome patients","volume":"6","author":"Sciascia","year":"2019","journal-title":"Front Med (Lausanne)"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2018.00114","article-title":"Anti-high-density lipoprotein antibodies and antioxidant dysfunction in immune-driven diseases","volume":"5","author":"Rodr\u00edguez-Carrio","year":"2018","journal-title":"Front Med (Lausanne)"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics12030647","article-title":"The past, present, and future in antinuclear antibodies (ANA)","volume":"12","author":"Irure-Ventura","year":"2022","journal-title":"Diagnostics"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-021-05033-9","article-title":"Analysis of the impact of sex and age on the variation in the prevalence of antinuclear autoantibodies in Polish population: a nationwide observational, cross-sectional study","volume":"42","author":"Krzemie\u0144","year":"2022","journal-title":"Rheumatol Int"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3390\/medicina61010060","article-title":"Mortality in antinuclear antibody-positive patients with and without rheumatologic immune-related disorders: a large-scale population-based study","volume":"61","author":"Shani","year":"2025","journal-title":"Med (Kaunas)"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2015.03.578","article-title":"Antinuclear antibodies are associated with all-cause mortality and cardiovascular outcomes in the general population","volume":"65","author":"Solow","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kep288","article-title":"Autoimmunity and atherosclerosis: the presence of antinuclear antibodies is associated with decreased carotid elasticity in young women. The Cardiovascular Risk in Young Finns Study","volume":"48","author":"Pertovaara","year":"2009","journal-title":"Rheumatology"},{"key":"B47","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1097\/BOR.0b013e32801127c8","article-title":"Smoking as a trigger for inflammatory rheumatic diseases","volume":"19","author":"Klareskog","year":"2007","journal-title":"Curr Opin Rheumatol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.022145","article-title":"Antinuclear and antiphospholipid autoantibodies in patients with peripheral arterial occlusive disease","volume":"64","author":"Kroeger","year":"2005","journal-title":"Ann Rheumatic Dis"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1111\/joim.13022","article-title":"The antiphospholipid syndrome \u2013 often overlooked cause of vascular occlusions","volume":"287","author":"Svenungsson","year":"2020","journal-title":"J Intern Med"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14030733","article-title":"Antiphospholipid syndrome: a comprehensive clinical review","volume":"14","author":"Patriarcheas","year":"2025","journal-title":"JCM"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1024\/0301-1526\/a000545","article-title":"Antiphospholipid antibodies and lower extremity peripheral arterial disease - a systematic review and meta-analysis","volume":"45","author":"Gavier","year":"2016","journal-title":"Vasa"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(00)00600-8","article-title":"Association between anticardiolipin antibodies and mortality in patients with peripheral arterial disease","volume":"109","author":"Puisieux","year":"2000","journal-title":"Am J Med"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.22617","article-title":"Impaired ankle\u2010brachial index in antiphospholipid syndrome: Beyond the traditional risk factors","volume":"33","author":"Caraiola","year":"2019","journal-title":"Clin Lab Anal"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1160\/TH09-11-0772","article-title":"Thrombophilic risk factors and peripheral arterial disease severity","volume":"104","author":"Sartori","year":"2010","journal-title":"Thromb Haemost"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22066","article-title":"Estimated frequency of antiphospholipid antibodies in patients with pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis: A critical review of the literature","volume":"65","author":"Andreoli","year":"2013","journal-title":"Arthritis Care Res"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2025-005464","article-title":"Influence of body mass index on cardiovascular risk in rheumatoid arthritis varies across anti-citrullinated protein antibody status and biologic use","volume":"11","author":"Karpouzas","year":"2025","journal-title":"RMD Open"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1002\/art.39198","article-title":"Rheumatoid arthritis, anti\u2013cyclic citrullinated peptide positivity, and cardiovascular disease risk in the women\u2019s health initiative","volume":"67","author":"Mackey","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2017.02.010","article-title":"Anti-MYC-associated zinc finger protein antibodies are associated with inflammatory atherosclerotic lesions on 18 F-fluorodeoxyglucose positron emission tomography","volume":"259","author":"Ernst","year":"2017","journal-title":"Atherosclerosis"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01595","article-title":"Antibodies against MYC-associated zinc finger protein: An independent marker in acute coronary syndrome","volume":"8","author":"Ernst","year":"2017","journal-title":"Front Immunol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"14552","DOI":"10.1038\/s41598-019-51125-9","article-title":"Lowered anti-beta1 adrenergic receptor antibody concentrations may have prognostic significance in acute coronary syndrome","volume":"9","author":"Ernst","year":"2019","journal-title":"Sci Rep"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2022.2070475","article-title":"Antibodies against phosphorylcholine and protection against atherosclerosis, cardiovascular disease and chronic inflammation","volume":"18","author":"Frosteg\u00e5rd","year":"2022","journal-title":"Expert Rev Clin Immunol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1111\/joim.13234","article-title":"Identification of IgG1 isotype phosphorylcholine antibodies for the treatment of inflammatory cardiovascular diseases","volume":"290","author":"de Vries","year":"2021","journal-title":"J Intern Med"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacadv.2024.101298","article-title":"Antibodies against phosphorylcholine in prediction of cardiovascular disease among women: A population-based prospective cohort study","volume":"3","author":"Frosteg\u00e5rd","year":"2024","journal-title":"JACC Adv"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.tcm.2018.05.010","article-title":"Oxidized LDL and anti-oxidized LDL antibodies in atherosclerosis - novel insights and future directions in diagnosis and therapy","volume":"29","author":"Hartley","year":"2019","journal-title":"Trends Cardiovasc Med"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvx112","article-title":"A role for autoantibodies in atherogenesis","volume":"113","author":"Iseme","year":"2017","journal-title":"Cardiovasc Res"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2022.102815","article-title":"Lipoprotein oxidation may underlie the paradoxical association of low cholesterol with coronary atherosclerotic risk in rheumatoid arthritis","volume":"129","author":"Karpouzas","year":"2022","journal-title":"J Autoimmun"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-023-06744-z","article-title":"Antibodies against oxidized LDL and atherosclerosis in rheumatoid arthritis patients treated with biological agents: a prospective controlled study","volume":"43","author":"Papamichail","year":"2024","journal-title":"Clin Rheumatol"},{"key":"B68","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.atherosclerosis.2022.06.814","article-title":"Decrease serum anti-oxLDL antibody is an independent marker of peripheral arterial disease in peritoneal dialysis patients","volume":"355","author":"Wang","year":"2022","journal-title":"Atherosclerosis"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.3390\/metabo14020123","article-title":"ApoB100 and atherosclerosis: What\u2019s new in the 21st century","volume":"14","author":"Kounatidis","year":"2024","journal-title":"Metabolites"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/j.microc.2025.115124","article-title":"Development of a triabody-based immunoassay against a pathogenic epitope in human ApoB100 for the diagnosis and monitoring of atherosclerosis","volume":"218","author":"Wang","year":"2025","journal-title":"Microchem J"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.02.047","article-title":"Oxidation-specific biomarkers and risk of peripheral artery disease","volume":"61","author":"Bertoia","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-020-05326-x","article-title":"Plasma concentrations of lipoproteins and risk of lower-limb peripheral artery disease in people with type 2 diabetes: the SURDIAGENE study","volume":"64","author":"Bertrand","year":"2021","journal-title":"Diabetologia"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejvs.2016.05.004","article-title":"All cause chronic widespread pain is common in patients with symptomatic peripheral arterial disease and is associated with reduced health related quality of life","volume":"52","author":"Lindgren","year":"2016","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"B74","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s12891-016-0888-z","article-title":"Foot and ankle characteristics associated with falls in adults with established rheumatoid arthritis: a cross-sectional study","volume":"17","author":"Brenton-Rule","year":"2016","journal-title":"BMC Musculoskelet Disord"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.13717","article-title":"Relationship between lower limb vascular characteristics, peripheral arterial disease and gait in rheumatoid arthritis","volume":"22","author":"Tehan","year":"2019","journal-title":"Int J Rheum Dis"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1080\/08998280.2022.2096361","article-title":"Impact of systemic lupus erythematosus on in-hospital outcomes of peripheral artery disease-insight from the National Inpatient Sample database","volume":"35","author":"Shah","year":"2022","journal-title":"Proc (Bayl Univ Med Cent)"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1055\/s-0034-1393964","article-title":"Clinical assessment of patients with peripheral arterial disease","volume":"31","author":"Bailey","year":"2014","journal-title":"Semin Intervent Radiol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000896","article-title":"Calcinosis in systemic sclerosis","volume":"34","author":"Davuluri","year":"2022","journal-title":"Curr Opin Rheumatol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics14060637","article-title":"Calcinosis in rheumatic disease is still an unmet need: A retrospective single-center study","volume":"14","author":"Nita","year":"2024","journal-title":"Diagnostics (Basel)"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2023.1271100","article-title":"Lower limb arterial calcification and its clinical relevance with peripheral arterial disease","volume":"10","author":"Dong","year":"2023","journal-title":"Front Cardiovasc Med"},{"key":"B81","doi-asserted-by":"publisher","first-page":"495","DOI":"10.46497\/ArchRheumatol.2022.9255","article-title":"The effects of glucocorticoid treatment on cardiovascular system in patients with systemic lupus erythematosus","volume":"37","author":"Blachut","year":"2022","journal-title":"Arch Rheumatol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12216923","article-title":"Changes in arterial stiffness monitored using the cardio-ankle vascular index in patients with rheumatic disease receiving initial glucocorticoid therapy: A clinical pilot study","volume":"12","author":"Kaneko","year":"2023","journal-title":"J Clin Med"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1007\/s13105-025-01106-6","article-title":"The role of cell junctions in atherosclerosis: implications for inflammation, endothelial dysfunction, and plaque stability","volume":"81","author":"Dabravolski","year":"2025","journal-title":"J Physiol Biochem"},{"key":"B84","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.avsg.2024.12.076","article-title":"Biomarkers and social determinants in atherosclerotic arterial diseases: A scoping review","volume":"113","author":"Scalise","year":"2025","journal-title":"Ann Vasc Surg"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1016\/j.avsg.2023.04.029","article-title":"Serum levels of matrix metalloproteinases in patients undergoing endovascular intervention for peripheral arterial disease","volume":"94","author":"Giagtzidis","year":"2023","journal-title":"Ann Vasc Surg"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.3390\/biom15060853","article-title":"Matrix metalloproteinases 7 and 10 are prognostic biomarkers for systemic cardiovascular risk in individuals with peripheral artery disease","volume":"15","author":"Li","year":"2025","journal-title":"Biomolecules"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12040798","article-title":"Narrative review of biological markers in chronic limb-threatening ischemia","volume":"12","author":"Popescu","year":"2024","journal-title":"Biomedicines"},{"key":"B88","doi-asserted-by":"publisher","first-page":"15348","DOI":"10.1038\/s41598-024-65188-w","article-title":"An evaluation of inflammatory and endothelial dysfunction markers as determinants of peripheral arterial disease in those with diabetes mellitus","volume":"14","author":"Zaib","year":"2024","journal-title":"Sci Rep"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.13103","article-title":"Diagnosis and management of rheumatoid arthritis: a review","volume":"320","author":"Aletaha","year":"2018","journal-title":"JAMA"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2017.12.001","article-title":"Cardiovascular involvement in systemic rheumatic diseases: An integrated view for the treating physicians","volume":"17","author":"Lee","year":"2018","journal-title":"Autoimmun Rev"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.018671","article-title":"Lower limb arterial incompressibility and obstruction in rheumatoid arthritis","volume":"64","author":"Del Rinc\u00f3n","year":"2005","journal-title":"Ann Rheumatic Dis"},{"key":"B92","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s00296-025-05901-8","article-title":"Physical activity of older patients with rheumatoid arthritis","volume":"45","author":"Fedorchenko","year":"2025","journal-title":"Rheumatol Int"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keg083","article-title":"Rheumatoid arthritis and macrovascular disease","volume":"42","author":"Alkaabi","year":"2003","journal-title":"Rheumatol (Oxford)"},{"key":"B94","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1002\/art.33322","article-title":"Noncardiac vascular disease in rheumatoid arthritis: increase in venous thromboembolic events","volume":"64","author":"Bacani","year":"2012","journal-title":"Arthritis Rheum"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2019.100455","article-title":"Trends of cardiac complications in patients with rheumatoid arthritis: Analysis of the United States National Inpatient Sample; 2005-2014","volume":"46","author":"Bandyopadhyay","year":"2021","journal-title":"Curr Probl Cardiol"},{"key":"B96","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.jbspin.2018.03.016","article-title":"Relevance and feasibility of a systematic screening of multimorbidities in patients with chronic inflammatory rheumatic diseases","volume":"86","author":"Da\u00efen","year":"2019","journal-title":"Joint Bone Spine"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1002\/art.20661","article-title":"Effect of glucocorticoids on the arteries in rheumatoid arthritis","volume":"50","author":"Del Rinc\u00f3n","year":"2004","journal-title":"Arthritis Rheumatism"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-eular.2489","article-title":"TNF-related apoptosis-inducing ligand and cardiovascular disease in rheumatoid arthritis","volume":"33","author":"Dessein","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2017-311214","article-title":"Cardiovascular and type 2 diabetes morbidity and all-cause mortality among diverse chronic inflammatory disorders","volume":"103","author":"Dregan","year":"2017","journal-title":"Heart"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1177\/2050312120958844","article-title":"Incident arterial vascular events in a cohort of Puerto Ricans with rheumatoid arthritis","volume":"8","author":"Gonz\u00e1lez-Mel\u00e9ndez","year":"2020","journal-title":"SAGE Open Med"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1007\/s00508-015-0767-x","article-title":"Can the ankle brachial pressure index (ABPI) and carotis intima media thickness (CIMT) be new early stage markers of subclinical atherosclerosis in patients with rheumatoid arthritis","volume":"127","author":"Kurt","year":"2015","journal-title":"Wien Klin Wochenschr"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.115.002867","article-title":"Hydroxychloroquine use is associated with decreased incident cardiovascular events in rheumatoid arthritis patients","volume":"5","author":"Sharma","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.201226","article-title":"Erectile dysfunction and cardiovascular risk in men with rheumatoid arthritis: a population-based cohort study","volume":"48","author":"Wilton","year":"2021","journal-title":"J Rheumatol"},{"key":"B104","doi-asserted-by":"publisher","first-page":"3891","DOI":"10.1038\/s41598-024-82987-3","article-title":"Genetic association between immune-mediated inflammatory diseases and peripheral artery disease: a Mendelian randomization study","volume":"15","author":"Wu","year":"2025","journal-title":"Sci Rep"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2018.07.002","article-title":"Foot and ankle characteristics in systemic lupus erythematosus: a systematic review and meta-analysis","volume":"48","author":"Stewart","year":"2019","journal-title":"Semin Arthritis Rheumatism"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa414","article-title":"Association of systemic lupus erythematosus with peripheral arterial disease: a meta-analysis of literature studies","volume":"59","author":"Forte","year":"2020","journal-title":"Rheumatology"},{"key":"B107","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s13256-019-2024-9","article-title":"Critical limb ischemia in a patient with systemic lupus erythematosus: a case report","volume":"13","author":"Damay","year":"2019","journal-title":"J Med Case Rep"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1177\/0961203310383069","article-title":"Unusual vascular focal high-grade arterial stenoses in a young woman with systemic lupus erythematosus and secondary antiphospholipid syndrome","volume":"20","author":"H\u00fcgli","year":"2011","journal-title":"Lupus"},{"key":"B109","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.berh.2016.03.003","article-title":"Cardiovascular risk and its modification in patients with connective tissue diseases","volume":"30","author":"O\u2019Sullivan","year":"2016","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"B110","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.semarthrit.2012.12.002","article-title":"The epidemiology of atherosclerotic cardiovascular disease among patients with SLE: a systematic review","volume":"43","author":"Schoenfeld","year":"2013","journal-title":"Semin Arthritis Rheumatism"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.3390\/jpm14030289","article-title":"Assessment of arterial stiffness and biochemical markers in systemic lupus erythematosus in the diagnosis of subclinical atherosclerosis","volume":"14","author":"Blachut","year":"2024","journal-title":"J Pers Med"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0182483","article-title":"Apolipoprotein L1 risk variants associate with prevalent atherosclerotic disease in African American systemic lupus erythematosus patients","volume":"12","author":"Blazer","year":"2017","journal-title":"PloS One"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000002121","article-title":"Risk of peripheral arterial occlusive disease in patients with systemic lupus erythematosus: a nationwide population-based cohort study","volume":"94","author":"Chuang","year":"2015","journal-title":"Med (Baltimore)"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.130817","article-title":"Peripheral arterial disease in systemic lupus erythematosus: prevalence and risk factors","volume":"41","author":"Erdozain","year":"2014","journal-title":"J Rheumatol"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2016-000190","article-title":"Predictors of peripheral arterial disease in SLE change with patient\u2019s age","volume":"4","author":"Erdozain","year":"2017","journal-title":"Lupus Sci Med"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-eular.3013","article-title":"Ankle-brachial index and arterial vascular events in systemic lupus erythematosus patients: a 5-year prospective cohort","volume":"38","author":"Erdozain","year":"2020","journal-title":"Clin Exp Rheumatol"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0b013e318156bbf5","article-title":"Systemic lupus erythematosus in a multiethnic US cohort (LUMINA L II): relationship between vascular events and the use of hormone replacement therapy in postmenopausal women","volume":"13","author":"Fern\u00e1ndez","year":"2007","journal-title":"J Clin Rheumatol"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000001183","article-title":"Cardiovascular events in systemic lupus erythematosus: a nationwide study in Spain from the RELESSER Registry","volume":"94","author":"Fern\u00e1ndez-Nebro","year":"2015","journal-title":"Med (Baltimore)"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.12025","article-title":"Peripheral arterial disease in patients with systemic lupus erythematosus: a prospective controlled study","author":"Hassan","year":"2013","journal-title":"Int J Rheum Dis"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kei014","article-title":"Systemic lupus erythematosus in a multiethnic cohort (LUMINA): XXVIII. Factors predictive of thrombotic events","volume":"44","author":"Ho","year":"2005","journal-title":"Rheumatol (Oxford)"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kex357","article-title":"Effect of long-term hydroxychloroquine on vascular events in patients with systemic lupus erythematosus: a database prospective cohort study","volume":"56","author":"Hsu","year":"2017","journal-title":"Rheumatol (Oxford)"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2019.01.044","article-title":"Systemic lupus erythematosus and increased prevalence of atherosclerotic cardiovascular disease in hospitalized patients","volume":"94","author":"Katz","year":"2019","journal-title":"Mayo Clin Proc"},{"key":"B123","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1177\/0961203314550223","article-title":"Prevalence of vascular disease in systemic lupus erythematosus compared with type-1 diabetes mellitus: a cross-sectional study of two cohorts","volume":"24","author":"Koenig","year":"2015","journal-title":"Lupus"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201760","article-title":"HLA-DRB1*04\/*13 alleles are associated with vascular disease and antiphospholipid antibodies in systemic lupus erythematosus","volume":"72","author":"Lundstr\u00f6m","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"B125","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1136\/ard.51.1.56","article-title":"Peripheral vascular disease in patients with systemic lupus erythematosus","volume":"51","author":"McDonald","year":"1992","journal-title":"Ann Rheum Dis"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2019-000346","article-title":"Development of a systemic lupus erythematosus cardiovascular risk equation","volume":"6","author":"Petri","year":"2019","journal-title":"Lupus Sci Med"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1002\/art.20622","article-title":"Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXIII. Baseline predictors of vascular events","volume":"50","author":"Toloza","year":"2004","journal-title":"Arthritis Rheum"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216764","article-title":"Impact of the new American College of Cardiology\/American Heart Association definition of hypertension on atherosclerotic vascular events in systemic lupus erythematosus","volume":"79","author":"Tselios","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-016-3610-4","article-title":"Arterial stiffness and peripheral arterial disease in patients with systemic lupus erythematosus","volume":"37","author":"Tziomalos","year":"2017","journal-title":"Rheumatol Int"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20122","article-title":"Atherosclerotic vascular events in a multinational inception cohort of systemic lupus erythematosus","volume":"62","author":"Urowitz","year":"2010","journal-title":"Arthritis Care Res"},{"key":"B131","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2018.01.022","article-title":"Cardiovascular disease in systemic lupus erythematosus is associated with increased levels of biomarkers reflecting receptor-activated apoptosis","volume":"270","author":"Wigren","year":"2018","journal-title":"Atherosclerosis"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0000000000000271","article-title":"Interarm blood pressure difference in patients with systemic lupus erythematosus","volume":"21","author":"Ye","year":"2015","journal-title":"J Clin Rheumatol"},{"key":"B133","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jaut.2016.10.004","article-title":"The antiphospholipid syndrome in patients with systemic lupus erythematosus","volume":"76","author":"Pons-Estel","year":"2017","journal-title":"J Autoimmun"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1177\/0961203320950477","article-title":"Antiphospholipid syndrome (APS) in patients with systemic lupus erythematosus (SLE) implies a more severe disease with more damage accrual and higher mortality","volume":"29","author":"Riancho-Zarrabeitia","year":"2020","journal-title":"Lupus"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1639065","article-title":"Novel advances on pathophysiological mechanisms, clinical manifestations, and treatment of antiphospholipid syndrome","volume":"16","author":"Zhu","year":"2025","journal-title":"Front Immunol"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1007\/s00281-022-00916-w","article-title":"Mechanisms of immunothrombosis and vasculopathy in antiphospholipid syndrome","volume":"44","author":"Knight","year":"2022","journal-title":"Semin Immunopathology"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1016\/j.rpth.2025.102724","article-title":"Unresolved issues in the diagnosis and management of thrombotic antiphospholipid syndrome","volume":"9","author":"Arachchillage","year":"2025","journal-title":"Res Pract Thromb Haemostasis"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1422.055","article-title":"Peripheral vascular occlusions leading to gangrene and amputations in antiphospholipid antibody positive patients","volume":"1108","author":"Asherson","year":"2007","journal-title":"Ann N Y Acad Sci"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2007.10.013","article-title":"Amputation of digits or limbs in patients with antiphospholipid syndrome","volume":"38","author":"Asherson","year":"2008","journal-title":"Semin Arthritis Rheumatism"},{"key":"B140","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.thromres.2021.12.001","article-title":"Cardiac and vascular features of arterial and venous primary antiphospholipid syndrome. The multicenter ATHERO-APS study","volume":"209","author":"Bucci","year":"2022","journal-title":"Thromb Res"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2018.09.010","article-title":"The association of adjusted Global AntiphosPholipid Syndrome Score (aGAPSS) with cardiovascular disease in subjects with antiphospholipid antibodies","volume":"278","author":"Di Minno","year":"2018","journal-title":"Atherosclerosis"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1177\/1538574417729273","article-title":"Surgical interventions for organ and limb ischemia associated with primary and secondary antiphospholipid antibody syndrome with arterial involvement","volume":"51","author":"Hinojosa","year":"2017","journal-title":"Vasc Endovascular Surg"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.13309","article-title":"Atherosclerosis and autoimmunity: a growing relationship","volume":"21","author":"Sanjadi","year":"2018","journal-title":"Int J Rheum Dis"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2013.03.013","article-title":"Cardiovascular disease in autoimmune rheumatic diseases","volume":"12","author":"Hollan","year":"2013","journal-title":"Autoimmun Rev"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.2147\/JIR.S417691","article-title":"Distinct features of vascular diseases in COVID-19","volume":"16","author":"Ceasovschih","year":"2023","journal-title":"JIR"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.31083\/j.fbs1504016","article-title":"Systemic sclerosis and atherosclerosis: potential cellular biomarkers and mechanisms","volume":"15","author":"Gerasimova","year":"2023","journal-title":"Front Bioscience-Scholar"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvs.2015.12.057","article-title":"Outcomes after open infrainguinal bypass in patients with scleroderma","volume":"64","author":"Arhuidese","year":"2016","journal-title":"J Vasc Surg"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.14158","article-title":"Arterial evaluation of systemic sclerosis patients with Doppler ultrasound: what did we find","volume":"24","author":"Badak","year":"2021","journal-title":"Int J Rheum Dis"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.111506","article-title":"Digital amputation in systemic sclerosis: prevalence and clinical associations. A retrospective longitudinal study","volume":"39","author":"Caramaschi","year":"2012","journal-title":"J Rheumatol"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-011-1878-y","article-title":"Severe vascular complications in patients affected by systemic sclerosis cyclically treated with iloprost","volume":"32","author":"Caramaschi","year":"2012","journal-title":"Rheumatol Int"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-021-05672-0","article-title":"Systemic sclerosis is associated with lower limb vascular stiffness and microvascular impairment: results from a prospective study","volume":"40","author":"Cassius","year":"2021","journal-title":"Clin Rheumatol"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2014.03.014","article-title":"Arterial vasculopathy in systemic sclerosis: computerized tomography (CT) angiographic features of macrovascular and microvascular upper limbs arteries","volume":"81","author":"Emad","year":"2014","journal-title":"Joint Bone Spine"},{"key":"B153","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1136\/ard.59.1.39","article-title":"Macrovascular disease and systemic sclerosis","volume":"59","author":"Ho","year":"2000","journal-title":"Ann Rheum Dis"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-048149","article-title":"Association between systemic sclerosis and peripheral arterial disease: a nationwide observation retrospective claim records cohort study in Taiwan","volume":"11","author":"Hsieh","year":"2021","journal-title":"BMJ Open"},{"key":"B155","doi-asserted-by":"publisher","first-page":"R87","DOI":"10.1186\/ar4267","article-title":"Ischemic arterial events and atherosclerosis in patients with systemic sclerosis: a population-based case-control study","volume":"15","author":"Nordin","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1136\/ard.57.8.476","article-title":"Distribution of macrovascular disease in scleroderma","volume":"57","author":"Stafford","year":"1998","journal-title":"Ann Rheum Dis"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1136\/ard.54.10.853","article-title":"Increased prevalence of symptomatic macrovascular disease in systemic sclerosis","volume":"54","author":"Veale","year":"1995","journal-title":"Ann Rheum Dis"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu227","article-title":"A longitudinal study of ankle brachial pressure indices in a cohort of patients with systemic sclerosis","volume":"53","author":"Wig","year":"2014","journal-title":"Rheumatol (Oxford)"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kead464","article-title":"The risk of major adverse cardiovascular events in patients with systemic sclerosis: a nationwide, population-based cohort study","volume":"63","author":"Yen","year":"2024","journal-title":"Rheumatol (Oxford)"},{"key":"B160","article-title":"Macrovascular involvement in systemic sclerosis: evidence of correlation with disease activity","volume":"30","author":"Zeng","year":"2012","journal-title":"Clin Exp Rheumatol"},{"key":"B161","unstructured":"Firestein & Kelley\u2019s textbook of rheumatology - clinicalKey"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1111\/joim.13525","article-title":"An update on polymyalgia rheumatica","volume":"292","author":"Lundberg","year":"2022","journal-title":"J Intern Med"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1002\/art.21311","article-title":"Direct medical costs of polymyalgia rheumatica","volume":"53","author":"Kremers","year":"2005","journal-title":"Arthritis Rheum"},{"key":"B164","doi-asserted-by":"publisher","first-page":"R50","DOI":"10.1186\/ar2664","article-title":"Increased risk of peripheral arterial disease in polymyalgia rheumatica: a population-based cohort study","volume":"11","author":"Warrington","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"B165","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1080\/03009742.2019.1628297","article-title":"Subclinical atherosclerosis and endothelial dysfunction in patients with polymyalgia rheumatica: a pilot study","volume":"49","author":"Santoro","year":"2020","journal-title":"Scandinavian J Rheumatol"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.140266","article-title":"Risk of vascular events in patients with polymyalgia rheumatica","volume":"186","author":"Hancock","year":"2014","journal-title":"CMAJ"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.26420\/austinjclincaserep.2017.1124","article-title":"A case of concomitant peripheral arterial obstructive disease and polymyalgia\u00a0rheumatica","volume":"4","author":"L","year":"2017","journal-title":"Austin J Clin Case Rep"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.110851","article-title":"Adverse events during longterm low-dose glucocorticoid treatment of polymyalgia rheumatica: a retrospective study","volume":"39","author":"Mazzantini","year":"2012","journal-title":"J Rheumatol"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003432","article-title":"Dose-dependent oral glucocorticoid cardiovascular risks in people with immune-mediated inflammatory diseases: a population-based cohort study","volume":"17","author":"Pujades-Rodriguez","year":"2020","journal-title":"PloS Med"},{"key":"B170","doi-asserted-by":"publisher","first-page":"11407","DOI":"10.1038\/s41598-020-68215-8","article-title":"An exploratory cross-sectional study of subclinical vascular damage in patients with polymyalgia rheumatica","volume":"10","author":"Scrivo","year":"2020","journal-title":"Sci Rep"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X221086710","article-title":"Psoriatic arthritis: prospects for the future","volume":"14","author":"Hackett","year":"2022","journal-title":"Ther Adv Musculoskeletal"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2025.103889","article-title":"Cardiovascular risk in psoriatic arthritis: How can we manage it","volume":"24","author":"Atzeni","year":"2025","journal-title":"Autoimmun Rev"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12155031","article-title":"Metabolic syndrome and its components have a different presentation and impact as cardiovascular risk factors in psoriatic and rheumatoid arthritis","volume":"12","author":"Atzeni","year":"2023","journal-title":"JCM"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2024.152389","article-title":"The management of cardiovascular risk in psoriatic disease: A bridge over troubled water","volume":"65","author":"Alunno","year":"2024","journal-title":"Semin Arthritis Rheumatism"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.2217\/ijr.12.68","article-title":"Psoriatic arthritis and risk of overt cardiovascular disease: review of the evidence","volume":"7","author":"Husted","year":"2012","journal-title":"Int J Clin Rheumatol"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.46497\/ArchRheumatol.2021.8083","article-title":"Assessment of subclinical atherosclerosis with ankle-brachial index in psoriatic arthritis: A case-control study","volume":"36","author":"Bilim","year":"2021","journal-title":"Arch Rheumatol"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2018.17421","article-title":"Higher incidence rates of comorbidities in patients with psoriatic arthritis compared with the general population using U.S. administrative claims data","volume":"25","author":"Kaine","year":"2019","journal-title":"J Manag Care Spec Pharm"},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-019-04528-y","article-title":"Cardiac and cardiovascular morbidities in patients with psoriatic arthritis: a population-based case control study","volume":"38","author":"Kibari","year":"2019","journal-title":"Clin Rheumatol"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-024-06890-y","article-title":"Sj\u00f6gren\u2019s disease activity associates with cardiovascular disease and monoclonal gammopathy: a university cohort study of disease activity and comorbidities","volume":"43","author":"Bohman","year":"2024","journal-title":"Clin Rheumatol"},{"key":"B180","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-023-06686-6","article-title":"Risk factors for cardiovascular disease in primary Sj\u00f6gren\u2019s syndrome (pSS): a 20-year follow-up study","volume":"42","author":"Santos","year":"2023","journal-title":"Clin Rheumatol"},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2021.03.030","article-title":"Systemic conditions associated with severity of dry eye signs and symptoms in the dry eye assessment and management study","volume":"128","author":"Yu","year":"2021","journal-title":"Ophthalmology"},{"key":"B182","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2020.107614","article-title":"Statins and autoimmunity: state-of-the-art","volume":"214","author":"Dehnavi","year":"2020","journal-title":"Pharmacol Ther"},{"key":"B183","doi-asserted-by":"publisher","DOI":"10.1038\/srep09902","article-title":"A systematic review and meta-analysis of the effect of statins on plasma asymmetric dimethylarginine concentrations","volume":"5","author":"Serban","year":"2015","journal-title":"Sci Rep"},{"key":"B184","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000035088","article-title":"The efficacy of statins in the treatment of rheumatoid arthritis: A systematic review and meta-analysis","volume":"102","author":"Ren","year":"2023","journal-title":"Med (Baltimore)"},{"key":"B185","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1016\/j.semarthrit.2015.10.013","article-title":"A review of the effects of statins in systemic sclerosis","volume":"45","author":"Ladak","year":"2016","journal-title":"Semin Arthritis Rheum"},{"key":"B186","doi-asserted-by":"publisher","DOI":"10.1002\/rai2.12169","article-title":"Effect of statins on psoriasis severity: A meta\u2010analysis of randomized clinical trials","volume":"5","author":"Abreu Lopez","year":"2025","journal-title":"Rheumatol Autoimmun"},{"key":"B187","doi-asserted-by":"publisher","DOI":"10.3390\/cells14050353","article-title":"Statins as an adjunctive antithrombotic agent in thrombotic antiphospholipid syndrome: mechanisms and clinical implications","volume":"14","author":"Bucci","year":"2025","journal-title":"Cells"},{"key":"B188","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5114\/aoms.2015.49807","article-title":"Statin intolerance - an attempt at a unified definition. Position paper from an International Lipid Expert Panel","volume":"11","author":"Banach","year":"2015","journal-title":"Arch Med Sci"},{"key":"B189","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvac020","article-title":"Side effects of statins: from pathophysiology and epidemiology to diagnostic and therapeutic implications","volume":"118","author":"Ruscica","year":"2023","journal-title":"Cardiovasc Res"},{"key":"B190","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehac015","article-title":"Prevalence of statin intolerance: a meta-analysis","volume":"43","author":"Byty\u00e7i","year":"2022","journal-title":"Eur Heart J"},{"key":"B191","doi-asserted-by":"publisher","DOI":"10.1002\/jcsm.12960","article-title":"Step-by-step diagnosis and management of the nocebo\/drucebo effect in statin-associated muscle symptoms patients: a position paper from the International Lipid Expert Panel (ILEP)","volume":"13","author":"Penson","year":"2022","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"B192","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.pcad.2023.03.001","article-title":"Bempedoic acid in the management of lipid disorders and cardiovascular risk. 2023 position paper of the International Lipid Expert Panel (ILEP)","volume":"79","author":"Banach","year":"2023","journal-title":"Prog Cardiovasc Dis"},{"key":"B193","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.171389","article-title":"The effect of statin use on mortality in systemic autoimmune rheumatic diseases","volume":"45","author":"Jorge","year":"2018","journal-title":"J Rheumatol"},{"key":"B194","article-title":"Efecto de pravastatina m\u00e1s ezetimibe en el grosor intimamedia carot\u00eddea en pacientes con lupus eritematoso","volume":"53","author":"Vera-Lastra","year":"2015","journal-title":"Rev M\u00e9dica del Instituto Mexicano del Seguro Soc"},{"key":"B195","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000043133","article-title":"Efficacy and safety of low-dose rosuvastatin\/ezetimibe for dyslipidemia in patients with rheumatoid arthritis or osteoarthritis","volume":"104","author":"Bak","year":"2025","journal-title":"Med (Baltimore)"},{"key":"B196","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1124786","article-title":"Crosstalk between cholesterol metabolism and psoriatic inflammation","volume":"14","author":"Luo","year":"2023","journal-title":"Front Immunol"},{"key":"B197","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1177\/1759720X12468659","article-title":"Fibrates as therapy for osteoarthritis and rheumatoid arthritis? A systematic review","volume":"5","author":"van Eekeren","year":"2013","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"B198","doi-asserted-by":"publisher","first-page":"A247","DOI":"10.1136\/annrheumdis-2013-eular.771","article-title":"THU0243 A comparison of fenofibrate and simvastatin anti-inflammatory effects in the treatment of rheumatoid arthritis","volume":"72","author":"Shirinsky","year":"2013","journal-title":"Ann Rheumatic Dis"},{"key":"B199","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.biopha.2018.05.024","article-title":"Role of PCSK9 in lipid metabolism and atherosclerosis","volume":"104","author":"Lin","year":"2018","journal-title":"Biomedicine Pharmacotherapy"},{"key":"B200","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.04.054","article-title":"The evolving future of PCSK9 inhibitors","volume":"72","author":"Rosenson","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"B201","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.124.072756","article-title":"Intensive lowering of LDL cholesterol levels with evolocumab in autoimmune or inflammatory diseases: An analysis of the FOURIER trial","volume":"151","author":"Zimerman","year":"2025","journal-title":"Circulation"},{"key":"B202","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2012.10.027","article-title":"Low-dose colchicine for secondary prevention of cardiovascular disease","volume":"61","author":"Nidorf","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"B203","doi-asserted-by":"publisher","DOI":"10.1097\/FJC.0000000000000658","article-title":"The NLRP3 inflammasome inhibitor, OLT1177 (Dapansutrile), reduces infarct size and preserves contractile function after ischemia reperfusion injury in the mouse","volume":"73","author":"Toldo","year":"2019","journal-title":"J Cardiovasc Pharmacol"},{"key":"B204","doi-asserted-by":"publisher","DOI":"10.3390\/ANTIOX12030722\/S1","article-title":"Inhibiting NLRP3 inflammasome activation by CY-09 helps to restore cerebral glucose metabolism in 3\u00d7Tg-AD mice","volume":"12","author":"Han","year":"2023","journal-title":"Antioxidants"},{"key":"B205","doi-asserted-by":"publisher","DOI":"10.1016\/J.EJPHAR.2022.175091","article-title":"Therapeutic potential of MCC950, a specific inhibitor of NLRP3 inflammasome","volume":"928","author":"Li","year":"2022","journal-title":"Eur J Pharmacol"},{"key":"B206","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12237367","article-title":"Patient-related factors predicting stent thrombosis in percutaneous coronary interventions","volume":"12","author":"Anghel","year":"2023","journal-title":"J Clin Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1814953\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T05:50:19Z","timestamp":1776837019000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1814953\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,22]]},"references-count":206,"alternative-id":["10.3389\/fimmu.2026.1814953"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1814953","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,22]]},"article-number":"1814953"}}